Products
Home » Products » Antibody » Primary Antibody » PTRH2 antibody
PTRH2 antibody
Category:
Research Area:
- SPECIFICATIONS
- Product Name
- PTRH2 antibody
- Catalogue No.
- FNab06951
- Size
- 100μg
- Form
- liquid
- Purification
- Immunogen affinity purified
- Purity
- ≥95% as determined by SDS-PAGE
- Clonality
- polyclonal
- Isotype
- IgG
- Storage
- PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months (Avoid repeated freeze / thaw cycles.)
Immunogen
- Immunogen
- peptidyl-tRNA hydrolase 2
- Alternative Names
- BIT1 antibody, PTH2 antibody
- UniProt ID
- Q9Y3E5
- Observed MW
- 20 kDa
Application
- Tested Applications
- ELISA, WB, IHC, IF
- Recommended dilution
- WB: 1:500 - 1:2000; IHC: 1:50 - 1:200; IF: 1:10 - 1:100
Validated Images
HEK-293 cells were subjected to SDS PAGE followed by western blot with FNab06951(PTRH2 antibody) at dilution of 1:1000
Immunohistochemistry of paraffin-embedded rat brain using FNab06951(PTRH2 antibody) at dilution of 1:100
- Background
- The protein encoded by this gene is a mitochondrial protein with two putative domains, an N-terminal mitochondrial localization sequence, and a UPF0099 domain. In vitro assays suggest that this protein possesses peptidyl-tRNA hydrolase activity, to release the peptidyl moiety from tRNA, thereby preventing the accumulation of dissociated peptidyl-tRNA that could reduce the efficiency of translation. This protein also plays a role regulating cell survival and death. It promotes survival as part of an integrin-signaling pathway for cells attached to the extracellular matrix (ECM), but also promotes apoptosis in cells that have lost their attachment to the ECM, a process called anoikos. After loss of cell attachment to the ECM, this protein is phosphorylated, is released from the mitochondria into the cytosol, and promotes caspase-independent apoptosis through interactions with transcriptional regulators. This gene has been implicated in the development and progression of tumors, and mutations in this gene have been associated with an infantile multisystem neurologic, endocrine, and pancreatic disease (INMEPD) characterized by intellectual disability, postnatal microcephaly, progressive cerebellar atrophy, hearing impairment, polyneuropathy, failure to thrive, and organ fibrosis with exocrine pancreas insufficiency (PMID: 25574476). Alternative splicing results in multiple transcript variants encoding different isoforms.